Title
Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis.

Permalink
https://escholarship.org/uc/item/1zm2994n

Journal
PloS one, 11(4)

ISSN
1932-6203

Authors
Cheema, Amrita K
Maier, Irene
Dowdy, Tyrone
et al.

Publication Date
2016

DOI
10.1371/journal.pone.0151190

Peer reviewed
Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis

Amrita K. Cheema\textsuperscript{1,2*}, Irene Maier\textsuperscript{3*}, Tyrone Dowdy\textsuperscript{1}, Yiwen Wang\textsuperscript{4}, Rajbir Singh\textsuperscript{1}, Paul M. Ruegger\textsuperscript{5}, James Borneman\textsuperscript{5}, Albert J. Fornace, Jr\textsuperscript{1,2}, Robert H. Schiestl\textsuperscript{3,6,7*}

\textsuperscript{1} Department of Oncology, Georgetown University Medical Center, Washington, D.C., United States of America, \textsuperscript{2} Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, Washington, D.C., United States of America, \textsuperscript{3} Department of Environmental Health Sciences, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America, \textsuperscript{4} Department of Biostatistics, Biomathematics and Bioinformatics, Georgetown University Medical Center, Washington, D.C., United States of America, \textsuperscript{5} Department of Plant Pathology and Microbiology, University of California Riverside, Riverside, California, United States of America, \textsuperscript{6} Department of Pathology Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, \textsuperscript{7} Department of Radiation Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

\*These authors contributed equally to this work.

\*RSchiestl@mednet.ucla.edu

Abstract

Intestinal microbiota play a significant role in nutrient metabolism, modulation of the immune system, obesity, and possibly in carcinogenesis, although the underlying mechanisms resulting in disease or impacts on longevity caused by different intestinal microbiota are mostly unknown. Herein we use isogenic Atm-deficient and wild type mice as models to interrogate changes in the metabolic profiles of urine and feces of these mice, which are differing in their intestinal microbiota. Using high resolution mass spectrometry approach we show that the composition of intestinal microbiota modulates specific metabolic perturbations resulting in a possible alleviation of a glycolytic phenotype. Metabolites including 3-methylbutyrolactone, kyneurenic acid and 3-methyladenine known to be onco-protective are elevated in Atm-deficient and wild type mice with restricted intestinal microbiota. Thus our approach has broad applicability to study the direct influence of gut microbiome on host metabolism and resultant phenotype. These results for the first time suggest a possible correlation of metabolic alterations and carcinogenesis, modulated by intestinal microbiota in A-T mice.

Introduction

Ataxia telangiectasia (A-T) is a recessive genetic disorder of childhood that occurs in one out of 100,000 humans worldwide. A-T is a multi-system, progressive disorder associated with a high...
incidence of lymphoid malignancies [1]. Approximately 30–40% of A-T patients develop neoplasia during their life and more than 40% of all tumors in A-T patients are non-Hodgkin’s lymphomas, ~20% acute lymphocytic leukemias, and 5% Hodgkin’s lymphomas [2–6]. A-T patients suffer from compromised immune function, neurodegeneration, infections of the respiratory system, and increased mortality due to 1000-fold increase in malignancy [1, 7–9]. Although ground breaking studies have led to a better and deeper understanding of ataxia telangiectasia mutated (ATM) gene function [10, 11], no effective therapy is currently available to prevent cancer or progressive neurodegeneration.

Several laboratories have generated different strains of Atm-deficient (Atm⁻/⁻) mice and reported that Atm⁻/⁻ mice developed lymphomas and died between 2 and 5 months of age [12–16]. Later studies, including our own, showed that the onset of lymphoma can be drastically delayed till 7–12 months, which was not a result of genetic diversity [17–20]. Instead, it was found to be associated with changes in intestinal microbiota, including an increase in Lactobacillus johnsonii [21], and reduced lymphoma incidence was achieved by administering the antioxidant N-acetyl cysteine [19]. The inflammatory effect of normal intestinal microbiota compositions could shorten lifespan of mice compared to mice housed under sterile housing conditions. Subsequently, we generated Atm⁻/⁻ mice harboring different but well characterized intestinal microbiota, termed conventional microbiota (CM), and restricted microbiota (RM). Restricted microbiota harbor relatively few bacterial species, dominated by unclassified Bacteroidetes, and are free of known pathogens [22]. RM mice were originally obtained by Caesarean section and re-derived into the mouse colony with restricted flora adoptive mothers [23]. Sterile housing and a restriction of intestinal microbiota (in RM mice) yielded a 4.5-fold lower level of genetic instability, differences in acute leukocyte genotoxicity, inflammation markers, and a 2.5-fold delayed onset of lymphoma resulting in longevity as compared to mice with CM [21]. We further demonstrated that increased levels of L. johnsonii present in RM mice, led to low basal levels of chromosomal genotoxicity and inflammation in Atm⁻/⁻ mice compared to the CM mice [21, 24]. Given that energy metabolism has been implicated in oncogenesis, we hypothesized that the microbiome is likely to influence host metabolism resulting in an altered phenotype. In this study, we used a comparative fecal and urine metabolomics profiling approach to discern how either of the microbiota compositions, CM or RM, would impact the metabolic phenotype of Atm⁻/⁻ mice.

Gut microbiome are known to have a profound influence of a myriad of diseases including dementia, obesity and cancer, although the molecular implications of dysbiosis are yet to be elucidated [25]. For example, microbiota have been shown to influence energy metabolism, beta-oxidation of lipids, bile acid, glutamine and tryptophan metabolism, as well as oxidative stress and immune response metabolites [26, 27]. Most of recently reported studies focus on the regulatory and signaling pathways that are directly affected by microbiome in different patho-physiological conditions; however, there is a lack in studies that directly examine the metabolic consequences of alterations in gut microbiome.

Metabolomics is a qualitative and quantitative evaluation of alterations in endogenous metabolism in response to a specific perturbation in a biological system [28]. It represents the endpoint of genetic regulation and its impact on altered enzymatic activities and endogenous biochemical reactions in a cell [29]; thus characterizing precise changes in metabolism is likely to enable better understanding of how cells adapt to oxidative stress and minimize DNA damage and genomic instability. Moreover, correlation of metabolic profiles with gut microbiota offers to provide valuable insights into host-microbe interactions as well as valuable steps for achieving a breakthrough in personalized therapy paradigm [30–33]. Since ATM function influences cell signaling and metabolism [34], a metabolomics approach using isogenic mouse models differing only in microbiome composition should allow for a direct assessment of accumulated bacterial metabolites and the effects of the microbiome on metabolism [35].
Methods

Reagents and standards

Acetonitrile (ACN), methanol, and water (all LC-MS grade) were purchased from Fisher Scientific (NJ, USA). Debrisoquine, 4-nitrobenzoic acid (4-NBA), and heparin were purchased from Sigma (USA). All standard compounds used for tandem mass spectrometry based validation of metabolite identification were bought from Sigma. Lipid standards were ordered from Avanti Polar Inc. Other reagents for preparation and analyses of samples are described in the respective sections.

Animal housing and husbandry

The study was performed under the guidelines of the UCLA Animal Research Committee and specifically approved procedures for animal breeding, housing and sample collection in this study. Mice were housed under two types of specific pathogen free (SPF) conditions at UCLA Department of Laboratory and Animal Research, where either sterile (for RM), or non-sterile (for CM) food, water, and bedding were employed. Atm-/- mice harboring RM and CM microbiota were created by rederivation as described in Fujiwara et al. [23], and by antibiotic treatment [36] followed by orogastric gavage of CM feces, respectively. The same procedures were applied in wild type mice. Mice of the RM colony were maintained under strictly aseptic and sterile conditions at the animal facility of the Radiation Oncology Department for several years. Atm-/- mice were obtained by intercrossing Atm +/- mice and identified by genotyping as previously described [21]. CM and RM mice for the metabolomics study were born in the respective colonies and were not treated with antibiotics. Urine and fecal samples from male Atm-/- and Atm +/- (referred to as wild type, or WT) mice aged 6–8 months were investigated by metabolomics-based molecular phenotyping. The different mice strains used in this study were defined as follows: Atm-KO-RM (Atm knock out mice carrying restricted microbiota); Atm-KO-CM (Atm knock out mice carrying conventional microbiota); WT-RM (wild type mice carrying restricted microbiota); and WT-CM (wild type mice carrying conventional microbiota). All urines and feces were separately collected in Eppendorf tubes from individual mice. The urine samples were centrifuged and the supernatant was aliquoted and frozen at -80°C until further use. All experiments were performed using at least 5 mice per genotype for metabolomics and at least 3–4 mice for 16S RNA sequencing experiments.

Intestinal bacterial analysis

For this study, Illumina-based high-throughput sequencing of bacterial 16S rRNA genes from intestinal mucosa samples [37] was performed as described [38]. DNA was extracted from these samples using the PowerSoil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA, USA), and a 30-second bead-beating step using a Mini-Beadbeater-16 (BioSpec Products, Bartlesville, OK, USA).

Metabolite extraction and metabolomics profiling

Urine samples were processed as described previously [39] using 66% acetonitrile in water to precipitate any proteins or cellular debris. The samples were centrifuged, dried under vacuum, and stored at -80°C until analysis. Fecal samples were processed by initially sonicating in extraction solvent containing water and methanol (50% v/v) and internal standards, followed by addition of chloroform (1:1 v/v). The samples were centrifuged and the two biphasic layers were separated carefully. To each of the solvent phase two volumes of acetonitrile was added and mixed thoroughly by vortexing. The samples were incubated at -20°C for 4 hours to allow
protein precipitation followed by centrifugation. The supernatant was combined and dried under vacuum, and resuspended in water containing 5% methanol for MS analysis.

Metabolites extracted from urine and fecal samples were analyzed in the same batch with two technical replicates for each sample to assess chromatographic reproducibility. The sample queue was randomized to avoid bias. Each sample (5 µl) was injected onto a reverse-phase 50 × 2.1 mm Acquity 1.7µm BEH C18 column (Waters Corp, Milford, MA), using an Acquity UPLC (Waters Corporation, USA) system online with an electrospray quadrupole time-of-flight tandem mass spectrometer (ESI-Q-TOF) (QTOF Premiere, Waters Corporation, USA). Positive and negative ion mode were operated; the details of tune page parameters have been described before [39, 40]. Together, we performed a broad range metabolite extraction and used reversed phase chromatography that would support the detection of a broad class of metabolites for urine and fecal samples. These data were normalized to the ion intensity of the internal standards (debrisoquine and 4, nitrobenzoic acid) and weight of the fecal pellet (for fecal samples), or creatinine (for urine samples). A 500 pg/µL solution of sulfadimethoxine in 50% acetonitrile ([M + H]⁺, m/z 311.0814) was infused at 0.08 µL/min flow rate as the reference mass (lock mass) for accurate mass measurements. The quality control (QC) samples for each matrix comprised an aliquot of all samples in the study set, thus representing a universal set of metabolites. The QC sample was used to initially condition the column and thereafter, it was injected after every ten injections to account for reproducibility of the LC-MS data [41]. The coefficient of variance was examined for internal standards and creatinine in the QC samples and was found to be less than 15%. As explained above, five biological replicates per group were used for comparative profiling, while pooled QC samples were used for assessing technical reproducibility throughout each batch acquisition.

Statistical analysis of LC-MS data and Pathway Analysis

The UPLC-QTOF raw data files were converted into NetCDF format (Network Common Data Form) using the MassLynx software (Waters Corp, Milford, MA). Subsequently, the LC-MS data were preprocessed using XCMS software as described [42]. The normalized data were processed using Metaboanalyst software (2.0) [43] and univariate analysis methods. Principal components analysis (PCA) was performed as an exploratory analysis to check for inter-group variability based on overall metabolite profiles. The candidate markers were selected by examining each volcano plot thereby considering fold change threshold of 2 and statistical p-value less than 0.05. A Benjamini-Hochberg correction was applied, which estimates conservative q-values [44], to ensure control of the false discovery rate (FDR) at a significance level of 0.05. Relative quantitation was achieved for molecular ions using the UPLC-QTOF system by taking a ratio of normalized intensity of the respective for the ions of interest in the comparative groups. This approach has been used by several laboratories including ours in previously reported studies [45–48]. The significant peaks from the FDR-adjusted analysis were putatively identified based on their m/z against Metabosearch, which performs accurate mass-based metabolite search through four main online databases; the Human Metabolome Database (HMDB), Lipid Maps, Madison Metabolomics Consortium Database (MMCD), and Metline [49]. The mass tolerance was kept at 5 parts per million to minimize false positive identification. The identity of metabolites was subsequently confirmed by comparisons of fragmentation spectra and retention time with commercially available standard compounds using tandem mass spectrometry (MS-MS). Signal intensities of the differentially abundant metabolites were visualized as a heat map, wherein the log transformed data were hierarchically clustered by Pearson correlation and average linkage clustering. The mean signal intensity is colored black, red indicates above-mean intensity, green denotes below-mean intensity and the degree of
color saturation reflects the magnitude of intensity relative to the mean. Both, fecal and urine metabolomics data sets were analyzed using the Ingenuity Pathway Analysis (IPA) tool to score for correlative biochemical pathways.

Results

RM mice have a distinct phylotype-reduced and pathogen-depleted intestinal microbiota composition compared to CM mice

We created a mouse model with a selectively restricted microbiota, in which mice exhibit diminished T-cell immunity [37, 50], low risk for inflammatory infections, and high susceptibility to ionizing radiation in conjunction with proliferative pro-inflammatory T-cell signaling [22]. In prior research, the bacterial communities in feces from these mice were investigated by pyrosequencing of the bacterial 16S rRNA gene, and distinct profiles were identified for Atm⁻/⁻ and wild type mice bearing RM and CM microbiota, respectively [21, 22]. Since we have observed prolonged lifespans associated with a reduced number of B-cells in Atm⁻/⁻ RM mice [51], incidence of inflammatory non-Hodgkin B-cell lymphoma and neoplasia was suspected to be low. Consistent with these findings, pro-inflammatory Helicobacter hepaticus, another Helicobacter sp., and Bacteroides stercoris were less abundant or absent in RM mice compared to CM mice in mucosa samples of small intestine and colon (Table 1). Advanced Illumina-based high-throughput sequencing was newly applied to the deep sequencing of intestinal samples from WT mice. We next investigated whether an onco-protective phenotype could be associated with differentially abundant metabolites detected in RM mice as compared to CM mice.

Microbiota drive changes in urinary metabolomics profiles in Atm⁻/⁻ and WT mice

To investigate microbiota-associated metabolic alterations, we performed comparative metabolomic profiling of urine samples obtained from Atm⁻/⁻ or Atm⁻/⁺ (wild type, or WT) mice harboring either the RM or CM microbiota. Pre-processing using XCMS resulted in a three dimensional data matrix (m/z, retention time, and intensity values) consisting of a total of 1588 (Atm⁻/⁻ KO-RM), 1672 (Atm⁻/⁻ KO-CM), 1465 (WT-RM) and 1575 (WT-CM) features that

| Nearest Cultured Relative (accession) (% identity) (Differentially abundant in intestine) | CM   | RM   | P     |
|--------------------------------------------|------|------|-------|
| Unclassified Bacteroidetes (AY239461) (94% identity) | 8%   | 49%  | 0.049 |
| Barnesiella intestinohominis (AB547647) (95% identity) | 0%   | 4%   | 0.029 |
| Nearest Cultured Relative (accession) (% identity) (Differentially abundant in colon) | CM   | RM   | P     |
| Helicobacter hepaticus ATCC 51449 (NR_102911) (100% identity) | 17%  | 0%   | 0.013 |
| Helicobacter sp. MIT 04--8588 (GU902718) (100% identity) | 11%  | 0%   | 0.002 |
| Bacteroides stercoris (AB714307) (100% identity) | 8%   | 0%   | 0.038 |
| Unclassified Bacteroidetes (AY239461) (94% identity) | 12%  | 49%  | 0.003 |
| Unclassified Bacteroidetes (AY239461) (96% identity) | 2%   | 5%   | 0.017 |

Values in CM and RM columns are % of Illumina rRNA gene reads from intestinal mucosal samples. These values were compared by 2-tailed Student’s T-Tests. n = 3–4 mice for each of the two colonies. CM is conventional microbiota. RM is restricted microbiota. % identity was determined by analyses using Blast (NCBI) [59].

doi:10.1371/journal.pone.0151190.t001
Candidate markers were selected by examining the volcano plot and considering a fold change threshold of 2 and p-value less than 0.05 (Fig 1, Panels A and C). Principal component analysis resulted in a reasonable class separation of Atm-KO and WT groups harboring CM or RM microbiota, respectively (Fig 1, Panels B and D). The identity of some metabolites was confirmed using tandem mass spectrometry (Table 2) and these are visualized as a heat map (Fig 2). For some other metabolites that came up as being significantly dysregulated on the volcano plots we were unable to find biological annotations in the databases. Interestingly, the presence of RM microbiota influenced both genotypes in a similar manner, although changes in the levels of urinary citrate were not
significant for the WT mice. The urinary levels of 3-methylbutyrolactone were found to be high in Atm-KO-RM and WT-RM mice. Additionally, mice with RM microbiota also showed elevation of methyladenine, while the levels of metabolites like sarcosine, N-acetyl serine, and N-acetyl glutamine were depleted in mice of both genotypes with RM as compared to CM.

Table 2. Validated urine metabolites that were differentially abundant in RM as compared to CM in Atm-KO and WT mice.

| Name of the Metabolite | ESI Mode | m/z* | RT ** | Atm KO FC*** | p-value | q-value | WT FC*** | p-value | q-value | Major CID Fragments |
|------------------------|----------|------|-------|--------------|---------|---------|----------|---------|---------|---------------------|
| Thymidine              | POS      | 243.0998 | 4.0   | ↑ <0.0001    | 0.0011  | 0.0001  | ↑ 0.0062 | 0.0129  | 170.0746, 172.0893 |
| 3-Methylbutyrolactone  | POS      | 101.0603 | 1.2   | ↑ 0.0001     | 0.0009  | 0.0070  | ↑ 0.0166 | 0.0249  | 55.0550, 73.0661, 83.0524 |
| Methyladenine          | POS      | 150.0778 | 0.4   | ↑ 0.0011     | 0.0037  | 0.0937  | ↑ 0.1125 | 85.0291, 87.0086, 111.0085 |
| Citric acid            | NEG      | 191.0182 | 0.3   | ↑ <0.0001    | 0.0001  | <0.0001 | ↓ 0.0001 | 0.0002  | 125.0736, 145.0646 |
| Acetyl-L-glutamine     | NEG      | 187.0717 | 0.3   | ↓ 0.0001     | 0.0009  | <0.0001 | ↓ 0.0001 | 0.0002  | 72.04 |
| Sarcosine              | POS      | 90.0541  | 1.1   | ↓ 0.4276     | 0.4528  | ↓ <0.0001 | 0.0026 | 74.252, 84.0457, 98.0257 |

* m/z = Mass/charge;
** RT = Retention Time in minutes;
*** FC = Fold Change = RM/CM (≤ 0.5 or ≥ 2.0);
q-value = False Discovery Rate (FDR) adjusted p-value.

doi:10.1371/journal.pone.0151190.t002

Fig 2. Heat map showing differential abundance of urine metabolites in the various study groups: Metabolites profiles for Atm-KO-CM group, Atm-KO-RM, WT-CM, and WT-RM, respectively. Each column represents a sample, and each row represents a metabolite. The mean signal intensity of CM group is colored black; red indicates above-mean intensity, green denotes below mean intensity, and the degree of color saturation reflects the magnitude of intensity relative to the mean.

doi:10.1371/journal.pone.0151190.g002
mice. Additionally, Atm-KO-RM mice showed upregulation of metabolites participating in TCA cycle like aconitic acid, and substituted amino acids as intermediary metabolites of purine like nicotinate D-ribonucleoside (Table 3). WT-RM mice showed an increase in the urinary levels of N-phosphoacetyl-L-asparatic acid; a metabolite that has been shown to have a strong anti-tumor activity (Table 4) [52]. Both genotypes of RM mice showed differential abundance of a number of di- and tripeptides differing in composition.

Microbiota drive alterations in the fecal metabolome in Atm<sup>−/−</sup> and WT mice

Next we performed metabolomic profiling of fecal samples obtained from Atm<sup>−/−</sup> or wild type (WT) mice harboring either the RM or CM microbiota. Pre-processing using XCMS resulted in 1478 (Atm<sup>−/−</sup>-KO-RM), 1742 (Atm<sup>−/−</sup>-KO-CM), 1655 (WT-RM) and 1675 (WT-CM) features that were subjected to multivariate analyses. Putative markers were selected by examining the volcano plot and considering a fold change threshold of 2 and p-value less than 0.05 (Fig 3, Panels A and C). Again, principal component analysis resulted in clear separation of Atm<sup>−/−</sup> and WT groups harboring CM or RM microbiota, respectively (Fig 3, Panels B and D). The identity of these metabolites was confirmed using tandem mass spectrometry (Table 5). Metabolites identified from individual difference detection analyses were visualized as a heat map.
Atm-KO and WT-RM mice showed statistically significant upregulation of a number of metabolites including homophenylalanine, sphinganine, methyluridine and riboflavin sodium phosphate. There was an elevation in the levels of kynurenic acid (a tryptophan metabolite) [53]. RM mice also showed elevation in the fecal levels of riboflavin phosphate (Vitamin B2), which is a precursor of flavin adenine dinucleotide (FAD) and flavin adenine mononucleotide (FMN) that are essential cofactors of TCA cycle. In addition, Atm-KO-RM mice showed alterations in relative abundance of free fatty acids, secondary bile acids as well as tripeptides as compared to the Atm-KO-CM mice (Table 6). WT-RM mice showed differentials levels of a number of glycerophospholipids, di- and tripeptides as well as fatty acids (Table 7).

In order to gain insights into metabolite enrichment representing specific molecular networks and pathway perturbations caused by changes in gut microbiome in Atm- KO mice, we used the Ingenuity Pathway Analysis (IPA) tool. This was achieved by integrating the fecal and urine metabolomics data sets that were initially scored separately for differentially expressed metabolites. Pathway analysis showed positive correlation for metabolic intermediates of TCA cycle and other relevant pathways.
cycle in RM as compared to CM in Atm-KO mice (Fig 5 Panel A). Examination of molecular networks revealed an upregulation of TP53 regulated metabolite networks (Fig 5 Panel B). Although these networks may affect a broad range of cellular processes, they can be considered distinct key metabolites that help explain the observed phenotype in these mice. Further investigations into more specific metabolite changes may answer to the basic question of precisely how do changes in microbiota composition result in an onco-protective phenotype.

**Discussion**

Despite increasing efforts in the field of A-T research, the mechanisms by which enteric microbiota lead to changes in Atm-mediated lymphomagenesis remain elusive. ATM regulates the
cellular response to oxidative stress and it senses double-stranded DNA breaks, thus inhibiting cell cycle progression [11, 54]. It has been demonstrated that intestinal microbiota can induce cancer development [35], for example Helicobacter pylori, inducing gastric cancer and lymphoma in WT mice and humans, as well as potentially influencing the response of cancer to therapies [55, 56]. We have previously shown reduction of cancer susceptibility and an impact on longevity by specific alterations in gut microbiota composition in Atm−/− mice. Using an untargeted, high resolution mass spectrometry approach, we then asked how this translates into metabolic changes in mice that are genetically identical but differ only in their gut microbiome composition. Surprisingly, we did not find differently abundant metabolites in blood profiles (data not shown). Moreover, our results from the analysis of urine and fecal samples suggest that distinct intestinal microbiota cause a metabolic shift towards the upregulation of metabolites including kynurenic acid, methyladenine and 3-methybutyrolactone that may attenuate cancer-promoting signaling pathways, reported to be associated with an onco-protective phenotype independent of the genotype of the mice. We found that intestinal microbiota restriction in Atm-deficient mice led to a 2.5-fold extension of lymphoma latency and 4 fold increased longevity, and significant differences in chromosomal genotoxicity, oxidative DNA damage and inflammation; our research was the first to show a relationship between intestinal microbiota and lymphoma onset [21]. Lactobacillus johnsonii, one of the indicator phylotypes that we identified to be more abundant in RM than CM mice, is known to increase the number of Paneth cells, which are a host cell type that produces antimicrobial compounds, and are located together with stem cells in the intestinal crypt [57]. The extended lifespans of our RM mouse models appear to be caused by an intestinal microbiota comprised largely of unclassified members of the Bacteroidetes (Table 1), which in turn result in specific metabolotypes.

### Table 5. Validated fecal metabolites that were differentially abundant in RM as compared to CM in the Atm-KO and WT mice.

| Metabolite Name                           | ESI Mode | m/z* | RT ** | Atm KO          | WT              | Major CID Fragments                  |
|-------------------------------------------|----------|------|-------|-----------------|-----------------|--------------------------------------|
| Palmitoyl-Ethanolamide                    | POS      | 300.2896 | 2.5   | 0.0053          | 0.0119          | FC*** 0.0083 0.0131 62.0612, 95.0872 |
| Homophenylalanine                         | POS      | 180.1006 | 0.9   | 0.0046          | 0.0113          | FC*** 0.0007 0.0031 97.0512, 117.0698 |
| 3-Methyluridine                           | NEG      | 257.0775 | 0.4   | 0.0003          | 0.0013          | FC*** <0.0001 0.0003 82.0300, 154.0508, 214.0718 |
| O-Benzyl-L-Tyrosine                       | POS      | 272.1293 | 0.4   | 0.0009          | 0.0033          | FC*** 0.006 0.0129 91.0553, 226.1236, 255.1023 |
| Dihydroceramide C2                        | POS      | 344.3183 | 3.1   | 0.0023          | 0.007           | FC*** 0.0078 0.0131 81.0711, 95.0867, 266.2828 |
| Sphinganine                               | POS      | 302.3049 | 2.5   | 0.0011          | 0.0037          | FC*** 0.008 0.0131 91.0552, 254.2855 |
| 3-hydroxyphenyl-Arachidonoyl amide        | POS      | 396.2922 | 3.7   | <0.0001         | 0.0003          | FC*** 0.0601 0.0738 110.0616, 203.1800 |
| Kynurenic acid                            | NEG      | 188.0365 | 1.7   | 0.0171          | 0.025           | FC*** 0.1489 0.1711 144.044 |
| Cytidine                                 | NEG      | 242.0764 | 1.2   | 0.0429          | 0.0538          | FC*** 0.0405 0.0521 109.0395 |
| Riboflavin sodium phosphate               | NEG      | 477.0794 | 0.3   | 0.0261          | 0.0371          | FC*** 0.1368 0.1606 78.9596, 96.9696 |
| Thymine                                  | POS      | 127.0495 | 0.6   | 0.031           | 0.043           | FC*** 0.0391 0.0515 84.0450, 110.0238 |
| Isonicotinic acid                         | POS      | 124.0405 | 0.4   | 0.1739          | 0.1956          | FC*** 0.0322 0.0434 80.0504, 96.0450, 124.0398 |
| Adenosine                                | POS      | 268.1035 | 0.6   | 0.2196          | 0.2371          | FC*** 0.0082 0.0131 94.0413, 136.0631 |
| LysoPE(18:1(9Z)/0:0)                      | NEG      | 478.2967 | 3.5   | 0.2118          | 0.2334          | FC*** 0.0045 0.0113 78.9599, 281.2458 |

* m/z = Mass/charge;  
** RT = Retention Time in minutes;  
*** FC = Fold Change = RM/CM (≤ 0.5 or ≥ 2.0);  
q-value = False Discovery Rate (FDR) adjusted p-value.

doi:10.1371/journal.pone.0151190.t005
Potentially chemopreventive metabolites were found to be differentially abundant in a microbiota-dependent manner in Atm-KO or WT mice; for example, the urinary levels of 3-methylbutyrolactone were elevated in both genotypes harboring RM microbiota. This metabolite is known to be produced by the intestinal bacteria and exhibits strong anti-aromatase properties [58]. Further, this metabolite inhibits fatty acid synthase (FAS), which activates carnitine palmitoyltransferase 1beta (CPT-1beta) and ultimately results in beta-oxidation of long chain fatty acids and prevention of lipid accumulation [59]. In addition, alpha-methylbutyrolactone acts as a selective alkylating agent for thiol rich enzymes like phosphofructokinase, DNA polymerase and glycogen synthase; thus regulating cell proliferation [60]. Additionally, mice with RM microbiota showed elevation of methyladenine, which is a potent inhibitor of phosphoinositide 3-kinases (PI3K) and has also been shown to exhibit tumor suppressor activity [61–64]. There was an elevation in the levels of kynurenic acid (a tryptophan metabolite) in feces of RM mice. Walczak et al. have reported the potential chemopreventive role of this metabolite in colon cancer [53]. Elevation of kynurenic acid has been shown to positively correlate with immune tolerance [65–67]. An upregulation of metabolites participating in oxidative phosphorylation was found in RM as compared to CM in Atm-KO (Fig 5, Panel A) mice, as well as an upregulation of TP53 regulated molecular networks in RM mice (Fig 5, Panel B). Interestingly, TP53 is known to regulate the expression of TIGAR (TP53-induced Glycolysis and Apoptosis Regulator) that has been shown to downregulate glycolysis by lowering the endogenous levels of fructose 1,6 biphosphate [68]. This is an interesting finding, generating new hypothesis for investigating how alleviation of glycolytic phenotype in RM mice is induced. Future investigations in our laboratory will specifically follow the molecular links and associations proposed herein.
| Metabolite Name                              | ESI Mode | m/z*  | RT ** | Atm KO (Fecal) | FC*** | p-value |
|---------------------------------------------|----------|-------|-------|----------------|-------|---------|
| L-Methionine                                | NEG      | 148.0432 | 0.4   |                |       | 0.0014  |
| Tryptophan                                  | POS      | 205.0965 | 1.6   |                |       | 0.0374  |
| Hydroxydecanoedioic acid                    | NEG      | 217.1082 | 2.4   |                |       | 0.0231  |
| 6-Acetyl-D-glucose                          | NEG      | 221.0687 | 1.5   |                |       | 0.0053  |
| 9,12-Dioxo-dodecanedioic acid              | NEG      | 227.1280 | 3.4   |                |       | 0.0357  |
| Malonylcarnitine                            | POS      | 248.1122 | 0.4   |                |       | 0.0078  |
| AFMK (Acetyl-N-formyl-5-methoxkynurenamine) | NEG      | 263.1011 | 2.3   |                |       | 0.0035  |
| Heptanoylcarnitine                          | NEG      | 272.1844 | 2.9   |                |       | 0.0068  |
| trans-Farnesyl phosphate                    | NEG      | 301.1586 | 3.1   |                |       | 0.0243  |
| Ser Arg Gly                                 | NEG      | 317.1577 | 2.9   |                |       | 0.0213  |
| Ser Lys Ser                                 | NEG      | 319.1647 | 3.0   |                |       | 0.0044  |
| Met Val Ala                                 | POS      | 320.1669 | 2.9   |                |       | 0.0299  |
| Phe Arg                                     | NEG      | 320.1700 | 3.0   |                |       | 0.0050  |
| Eicosapentaenoyl ethanolamide               | POS      | 346.2734 | 3.1   |                |       | 0.0237  |
| Cys Gln Cys                                 | POS      | 353.0977 | 3.0   |                |       | 0.0143  |
| DHA ethyl ester                             | POS      | 357.2794 | 4.3   |                |       | 0.0465  |
| 3-Oxo-chol-11-enic acid                     | POS      | 373.2752 | 3.8   |                |       | 0.0425  |
| Ile Thr Phe                                 | POS      | 380.2167 | 7.5   |                |       | 0.0465  |
| Hydroxytetraenoic acid                      | NEG      | 381.3370 | 8.4   |                |       | 0.0158  |
| His Asp Asn                                 | NEG      | 383.1299 | 2.8   |                |       | 0.0002  |
| Allocholenoxychoolic acid                   | NEG      | 391.2852 | 4.3   |                |       | 0.0175  |
| Vitamin D6                                  | POS      | 411.3633 | 6.7   |                |       | 0.0474  |
| Lys His Met                                 | POS      | 415.2148 | 4.8   |                |       | 0.0257  |
| Lys-Tyr-OH                                  | NEG      | 416.1451 | 1.5   |                |       | 0.0239  |
| PA(17:1/0:0)                                | POS      | 423.2508 | 7.9   |                |       | 0.0269  |
| His Phe Met                                 | NEG      | 432.1713 | 1.1   |                |       | 0.0127  |
| PE(P-16:0/0:0)                              | NEG      | 436.2817 | 6.0   |                |       | 0.0283  |
| Met Met Arg                                 | POS      | 437.1989 | 4.8   |                |       | 0.0268  |
| PC(P-14:0/0:0)                              | NEG      | 450.3013 | 3.3   |                |       | 0.0171  |
| (22R)-1a,22,25-Trihydroxy-23,24-tetrahydro-24a,24b-dihomo-20-epivitamin D3 | NEG | 455.3139 | 5.3   |                |       | 0.0239  |
| Trp Trp Ala                                 | POS      | 462.2094 | 3.8   |                |       | 0.0222  |
| PA(22:2(13Z,16Z)/0:0)                       | NEG      | 489.2991 | 3.2   |                |       | 0.0050  |
| Trp Asp Trp                                 | POS      | 506.2044 | 4.0   |                |       | 0.0239  |
| D-Urobilinogen                              | POS      | 591.3198 | 3.1   |                |       | 0.0100  |
| Atalantine                                  | POS      | 611.2065 | 9.3   |                |       | 0.0006  |
| PA(P-16:0/15:1(9Z))                         | POS      | 617.4588 | 8.2   |                |       | 0.0067  |
| Cer(d18:0/24:0)                              | POS      | 652.6553 | 9.0   |                |       | 0.0186  |
| PG(14:1(9Z)/14:1(9Z))                       | POS      | 663.4281 | 8.2   |                |       | 0.0050  |
| Palmitoyl thio-PC                           | POS      | 750.5451 | 9.4   |                |       | 0.0484  |
| PA(18:1/22:4)                               | POS      | 751.5342 | 9.4   |                |       | 0.0475  |
| MGDG(18:2/18:3)                             | POS      | 777.5552 | 9.4   |                |       | 0.0426  |
| Pi(P-16:0/16:1)                             | POS      | 793.5189 | 8.3   |                |       | 0.0035  |
| 16:2-Glc-Campesterol                        | POS      | 797.6345 | 8.9   |                |       | 0.0103  |
| PG(18:1/20:2)                               | POS      | 801.5637 | 8.9   |                |       | 0.0049  |
| PC(16:1/22:6)                               | POS      | 804.5513 | 8.0   |                |       | 0.0488  |

* m/z = Mass/charge;
** RT = Retention Time in minutes;
*** FC = Fold Change = RM/CM (≤ 0.5 or ≥ 2.0).

doi:10.1371/journal.pone.0151190.t006
Table 7. Fecal metabolites that were differentially abundant in RM as compared to CM only in WT mice.

| Name of Unique Metabolite ID | ESI Mode | m/z*   | RT ** | FC *** | p-value |
|------------------------------|----------|--------|-------|--------|---------|
| Alanine                      | POS      | 90.0550| 0.3   | ↓      | 0.0037  |
| 3-Amino-alanine              | POS      | 106.0743| 8.5   | ↑      | 0.0428  |
| Hydroxybenzoquinone          | POS      | 125.0230| 0.4   | ↓      | 0.0283  |
| 4-Hydroxyquinolone          | NEG      | 144.0448| 2.5   | ↓      | 0.0036  |
| Orotic acid                  | NEG      | 155.0106| 0.4   | ↓      | 0.0110  |
| Acetyl-β-Valine              | NEG      | 158.0810| 1.5   | ↑      | 0.0232  |
| 2-Hydroxylamino-4,6-dinitrotoluene | NEG  | 212.0314| 0.4   | ↓      | 0.0020  |
| 3-Methoxytryosine            | POS      | 212.0930| 1.3   | ↓      | 0.0043  |
| N-Acetyl-beta-D-glucosaminylamine | POS  | 221.1112| 1.4   | ↓      | 0.0438  |
| L-4-Hydroxy-3-methoxy-a-methylphenylalanine | POS | 226.1071| 1.5   | ↓      | 0.0118  |
| Gamma-glutamyl-proline       | NEG      | 242.1136| 2.3   | ↓      | 0.0238  |
| Palmitic acid                | NEG      | 255.2318| 7.4   | ↓      | 0.0176  |
| Asp Gln                      | POS      | 262.1058| 0.4   | ↓      | 0.0217  |
| AFMK (Formyl-N-acetyl-5-methoxykynurenamine) | POS | 265.1202| 2.3   | ↓      | 0.0316  |
| N-Acetyl-L-glutamate 5-phosphate | NEG | 268.0202| 0.3   | ↓      | 0.0018  |
| Isovalerylglucuronide        | NEG      | 277.0919| 1.3   | ↑      | 0.0068  |
| 2-methyl-16-heptadecenoic acid | NEG  | 281.2480| 7.5   | ↓      | 0.0374  |
| Met Gly Ser                  | NEG      | 292.0972| 0.5   | ↓      | 0.0019  |
| C20:4n-2,6;9;12              | NEG      | 303.2316| 7.0   | ↓      | 0.0484  |
| Arachidic acid               | NEG      | 311.2976| 8.4   | ↓      | 0.0106  |
| 3-Oxo-nonadecanoic acid      | POS      | 313.2747| 7.0   | ↓      | 0.0010  |
| His Gly Cys                  | POS      | 316.1097| 0.6   | ↑      | 0.0258  |
| Ser Pro Asp                  | NEG      | 316.1165| 0.6   | ↑      | 0.0161  |
| Leu Trp                      | POS      | 318.1815| 2.4   | ↓      | 0.0433  |
| Hydroxy sphinganine          | POS      | 318.3007| 4.9   | ↑      | 0.0122  |
| His Leu Gly                  | POS      | 326.1834| 1.7   | ↓      | 0.0130  |
| Docosanoic acid              | NEG      | 339.3246| 8.8   | ↓      | 0.0428  |
| 2,3-dinor Thromboxane B1     | NEG      | 343.2122| 2.9   | ↑      | 0.0345  |
| Leu Thr Leu                  | NEG      | 344.2169| 2.9   | ↑      | 0.0099  |
| 18-Oxo-resolvin E1           | NEG      | 347.1878| 3.2   | ↓      | 0.0391  |
| Coutaric acid                | NEG      | 348.1907| 3.2   | ↓      | 0.0400  |
| S-(2-Hydroxyethyl)glutathione | NEG  | 350.1028| 0.5   | ↑      | 0.0177  |
| MG(0:0/18:3/0:0)              | NEG      | 351.2510| 8.0   | ↓      | 0.0012  |
| 13,14-Dihydro PGF-1a         | NEG      | 357.2618| 3.7   | ↑      | 0.0211  |
| His Asn Cys                  | NEG      | 371.1180| 2.7   | ↓      | 0.0307  |
| Pro Glu Met                  | NEG      | 374.1379| 7.4   | ↓      | 0.0302  |
| Pro His Glu                  | NEG      | 380.1610| 7.0   | ↓      | 0.0434  |
| Lys-Lys-OH                   | NEG      | 381.1748| 7.5   | ↓      | 0.0461  |
| Pentacosanoic acid           | NEG      | 381.3723| 9.5   | ↓      | 0.0369  |
| Val Glu His                  | NEG      | 382.1763| 7.5   | ↓      | 0.0456  |
| S-Adenosylhomocysteine       | NEG      | 383.1160| 0.5   | ↑      | 0.0014  |
| Glu Phe Val                  | POS      | 394.1940| 2.0   | ↓      | 0.0232  |
| Hexacosanoic acid            | NEG      | 395.3859| 9.9   | ↓      | 0.0415  |
| PC(0:12:0:0:0)               | NEG      | 424.2795| 3.3   | ↓      | 0.0003  |
| Glu Arg Glu                  | NEG      | 431.1883| 4.8   | ↓      | 0.0077  |
| Palmityl myristoleate        | NEG      | 449.4324| 10.6  | ↓      | 0.0452  |

(Continued)
Table 7. (Continued)

| Name of Unique Metabolite ID | ESI Mode | m/z*  | RT ** | FC*** | p-value |
|-----------------------------|----------|-------|-------|-------|---------|
| PE(O-18:0/0:0)              | POS      | 468.3489 | 6.6   |       | 0.0054  |
| Sulfocholic acid            | NEG      | 487.2420 | 3.9   | ↓     | 0.0111  |
| Hydroxydihydrosterone glucuronide | NEG | 489.2540 | 3.9   | ↓     | 0.0109  |
| Glycochenodeoxycholate 7-sulfate | NEG | 528.2599 | 2.3   | ↓     | 0.0269  |
| Trp Arg Trp                 | NEG      | 545.2651 | 4.1   | ↓     | 0.0228  |
| DG(16:0/16:0/0:0)           | POS      | 569.5133 | 9.4   | ↑     | 0.0031  |
| Ceramide (d18:0/20:0)       | POS      | 596.5966 | 10.6  | ↑     | 0.0451  |
| PG(O-16:0/12:0)             | NEG      | 651.4610 | 7.9   | ↓     | 0.0037  |
| PG(14:0/14:0)               | NEG      | 665.4351 | 7.5   | ↓     | 0.0318  |
| Ceramide (t18:0/24:0)       | POS      | 668.6561 | 10.1  | ↑     | 0.0297  |

* m/z = Mass/charge;
** RT = Retention Time in minutes;
*** FC = Fold Change = RM/CM (≤ 0.5 or ≥ 2.0).

doi:10.1371/journal.pone.0151190.t007

Fig 5. Functional Pathway Analysis showing major upregulated pathways in Atm-KO mice with RM as compared to CM microbiota. Panel A shows significantly perturbed canonical pathways in Atm-KO-RM mice, while Panel B shows a TP53 regulated network that correlated strongly with metabolic profiles of Atm-KO-RM mice.

doi:10.1371/journal.pone.0151190.g005
Our results demonstrate that microbiome composition leads to specific changes in overall host metabolism, which may have direct implications on phenotype. This proof of principle investigation opens up several relevant and challenging questions; particularly, how lipids measured in feces of these mice indirectly regulate apoptosis, or if the altered metabolic profile accounts at least in part for extended life and decreased incidence of carcinogenesis in eukaryotes and will be a part of future studies. Further investigation is also needed to specify the regulatory role of certain microbiota compositions in permitting genotoxicity by reducing local or systemic autophagy.

In conclusion, our pilot study demonstrates metabolite profiles likely modulated by specific phylotypes in RM mice that correlate with our previously reported observations of decreased tumor incidence and general leukocyte genotoxicity in RM mice as compared to Atm-KO-CM mice [21]. These alterations in the mean abundance of the interrogated metabolites, including 3-methylbutyrolactone and 3-methyadenine (Fig 2) and kynurenic acid (Fig 4) were more pronounced in Atm-KO mice as compared to the WT RM mice, which may help explain genotype based susceptibility. Together, these findings lend credence to the notion that manipulating microbial composition could be used as an effective strategy to prevent or alleviate cancer susceptibility. The onco-protective effect of RM microbiota is true for WT as well as Atm-KO mice—the only difference lies in cancer susceptibility for both genotypes. Remarkably, our findings suggest that composition of the gut microbiota influences and alters central carbon metabolism in a genotype independent manner. In future, it is our hope that the use of probiotics-containing RM would be a potential chemopreventive for normal humans, while the same type of microbiota would decrease tumor incidence in cancer susceptible populations.

Acknowledgments
The authors would like to acknowledge the Proteomics and Metabolomics shared resource partially supported by NIH/NCI grant P30-CA051008.

Author Contributions
Conceived and designed the experiments: RHS AKC IM AF. Performed the experiments: IM AKC RS PMR JB. Analyzed the data: IM AKC YW TD. Contributed reagents/materials/analysis tools: RHS AKC AF IM JB. Wrote the paper: AKC IM RHS AF JB.

References
1. Meyn MS. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet. 1999; 55 (5):289–304. Epub 1999/07/28. PMID: 10422797.
2. Peterson RD, Funkhouser JD, Tuck-Muller CM, Gatti RA. Cancer susceptibility in ataxia-telangiectasia. Leukemia. 1992; 6 Suppl 1:8–13. PMID: 1548942.
3. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet. 1990; 46(1):9–19. PMID: 2184934.
4. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia- telangiectasia. J Natl Cancer Inst. 1986; 77(1):89–92. PMID: 3459930
5. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol. 1998; 31(6):491–7. PMID: 9835901.
6. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996; 87(2):423–38. PMID: 8555463.
7. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig Artic Ser. 1975; 11(1):255–70. PMID: 1096982.
8. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006; 91(7):610–1. PMID: 16790721.
9. Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001; 20(1):87–108. Epub 2001/03/28. CRIAI:20:1:87 [pii] doi: 10.1385/CRIAI:20:1:87 PMID: 11269230.

10. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petriji JH, et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 2000; 404(6778):613–7. doi: 10.1038/35007091 PMID: 10766245.

11. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003; 421(6922):499–506. doi: 10.1038/nature01368 PMID: 12556478.

12. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996; 86(1):159–71. PMID: 8689683.

13. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-Torres J, et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A. 1996; 93(23):13084–9. PMID: 8917548.

14. Xu Y, Ashley T, Brainer EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 1996; 10(19):2411–22. Epub 1996/10/01. PMID: 8843194.

15. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 1996; 10(19):2401–10. Epub 1996/10/01. PMID: 8843193.

16. Liyanage M, Weaver Z, Barlow C, Coleman A, Pankratz DG, Anderson S, et al. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood. 2000; 96(5):1940–6. Epub 2000/08/29. PMID: 10961898.

17. Borghesani PR, Alt FW, Bottaro A, Davidson L, Aksoy S, Rathbun GA, et al. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc Natl Acad Sci U S A. 1996; 93(7):3336–41. PMID: 10716718.

18. Petiniot LK, Weaver Z, Vaccio M, Shen R, Wangsa D, Barlow C, et al. RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Mol Cell Biol. 2002; 22(9):3174–7. PMID: 11940674.

19. Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst). 2006; 5(7):852–9. Epub 2006/06/20. S1568-7864(06)00120-0 [pii] doi: 10.1016/j.dnarep.2006.05.003 PMID: 16781197.

20. Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, et al. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet. 2004; 13(16):1793–802. Epub 2004/06/24. doi: 10.1093/hmg/ddh189 ddh189 [pii]. PMID: 15213104.

21. Yamamoto ML, Maier I, Dang AT, Berry D, Liu J, Ruegger PM, et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 2013; 73(14):4222–32. Epub 2013/07/19. doi: 10.1158/0008-5472.CAN-13-0022 PMID: 23860718; PubMed Central PMCID: PMC3718495.

22. Maier I, Berry DM, Schiestl RH. Intestinal microbiota reduces genotoxic endpoints induced by high-energy protons. Radiation research. 2014; 181(1):45–53. doi: 10.1667/RR13352.1 PMID: 24397477.

23. Fujiwara D, Wei B, Presley LL, Brewer S, McPherson M, Lewinski MA, et al. Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota. J Immunol. 2008; 180(9):5843–52. Epub 2008/04/22. 180/9/5843 [pii] PMID: 18424703.

24. Westbrook AM, Wei B, Braun J, Schiestl RH. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer research. 2009; 69(11):4827–34. Epub 2009/06/03. 69/11/4827 [pii] doi: 10.1158/0008-5472.CAN-08-4416 PMID: 19487293; PubMed Central PMCID: PMC2709766.

25. Zitvogel L, Galluzzi L, Viala S, Veltzou M, Dalliere R, Merad M, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015; 7(271):271ps1. doi:10.1126/scitranslmed.3010473 PMID: 25609166.

26. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009; 15(13):1546–58. PMID: 19442127.

27. Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: How prebiotic can work? Br J Nutr. 2013; 109 Suppl 2:S81–5. doi: 10.1017/S0007114513000407 PMID: 23360884.

28. Bowling FG, Thomas M. Analyzing the metabome. Methods in molecular biology. 2014; 1168:31–45. doi: 10.1007/978-1-4939-0847-9_3 PMID: 24870129.

29. Blow N. Metabolomics: Biochemistry’s new look. Nature. 2008; 455(7213):697–700. doi: 10.1038/455697a PMID: 18833281.

30. Xie G, Zhang S, Zheng X, Jia W. Metabolomics approaches for characterizing metabolic interactions between host and its commensal microbes. Electrophoresis. 2013; 34(19):2787–98. doi: 10.1002/elps.201300017 PMID: 23778228.
31. Clavel T, Desmarchelier C, Haller D, Gerard P, Rohn S, Lepage P, et al. Intestinal microbiota in metabolic diseases: From bacterial community structure and functions to species of pathophysiological relevance. Gut microb. 2014; 5(4). PMID: 25003516.

32. Swann JR, Claus SP. Nutrimetabolomics: nutritional applications of metabolic profiling. Science progress. 2014; 97(Pt 1):41–7. PMID: 24800468.

33. Ursell LK, Haiser HJ, Van Treuren W, Garg N, Reddivari L, Vanamala J, et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterology. 2014; 146(6):1470–6. doi: 10.1053/j.gastro.2014.03.001 PMID: 24631493.

34. Cheema AK, Timofeeva O, Varghese R, Dimtchev A, Shiekh K, Shulaev V, et al. Integrated analysis of ATM mediated gene and protein expression impacting cellular metabolism. Journal of proteome research. 2011; 10(5):2651–7. doi: 10.1021/pr1012433 PMID: 21322649.

35. Schwabe RF, Jobin C. The microbiome and cancer. Nature reviews Cancer. 2013; 13(11):800–12. Epub 2013/10/18. doi: 10.1038/nrc3610 PMID: 24132111.

36. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004; 118(2):229–41. Epub 2004/07/21. doi: 10.1016/j.cell.2004.07.002 S0092867404006610 [pii]. PMID: 15260992.

37. Presley LL, Wei B, Braun J, Borneman J. Bacteria associated with immunoregulatory cells in mice. Appl Environ Microbiol. 2010; 76(3):936–41. Epub 2009/12/17. AEM.01561-09 [pii] doi: 10.1128/AEM.01561-09 PMID: 20008175; PubMed Central PMCID: PMC2813032.

38. Ruegger PM, Clark RT, Weger JR, Braun J, Borneman J. Improved resolution of bacteria by high throughput sequence analysis of the rRNA internal transcribed spacer. Journal of microbiological methods. 2014; 105:82–7. doi: 10.1016/j.mimet.2014.07.001 PMID: 25034229; PubMed Central PMCID: PMC4160368.

39. Kaur P, Rizk N, Ibrahim S, Luo Y, Younes N, Perry B, et al. Quantitative metabolomic and lipidomic profiling reveals aberrant amino acid metabolism in type 2 diabetes. Molecular bioSystems. 2013; 9(2):307–17. doi: 10.1039/c2mb25384d PMID: 23247761.

40. Varghese RS, Cheema A, Cheema P, Bourbeau M, Tuil L, Zhou B, et al. Analysis of LC-MS data for characterizing the metabolic changes in response to radiation. Journal of proteome research. 2011; 10(5):2651–7. doi: 10.1021/pr1012433 PMID: 21322649.

41. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc. 2010; 5(6):1005–18. doi: 10.1038/nprot.2010.50 PMID: 20448546.

42. Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006; 78(3):779–87. Epub 2006/02/02. doi: 10.1021/ac051437y PMID: 16448051.

43. Xie J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyzer 2.0—a comprehensive server for metabolomic data analysis. Nucleic acids research. 2012; 40(Web Server issue):W127–33. Epub 2012/05/04. gks374 [pii] doi: 10.1093/nar/gks374 PMID: 22553367; PubMed Central PMCID: PMC3394314.

44. Storey JD. A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2002; 64(3):479–98.

45. Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ Jr, et al. UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem. 2008; 80(3):665–74. doi: 10.1021/ac051437y PMID: 18173289; PubMed Central PMCID: PMC2254319.

46. Ciappio ED, Krausz KW, Rochman C, Furusawa T, Bonzo JA, Tessarollo L, et al. Metabolomics Reveals a Role for the Chromatin-Binding Protein HMGN5 in Glutathione Metabolism. PLoS One. 2014; 9(1): e84583. doi: 10.1371/journal.pone.0084583 PMID: 24392144; PubMed Central PMCID: PMC3879345.

47. Cheema AK, Suman S, Kaur P, Singh R, Fornace AJ Jr, Datta K. Long-Term Differential Changes in Mouse Intestinal Metabolomics after gamma and Heavy Ion Radiation Exposure. PLoS One. 2014; 9(1): e87079. doi: 10.1371/journal.pone.0087079 PMID: 24475228; PubMed Central PMCID: PMC3903607.

48. Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ Jr, Gonzalez FJ, et al. Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiation research. 2009; 172(1):42–57. Epub 2009/07/08. doi: 10.1667/RR1703.1 PMID: 19580506; PubMed Central PMCID: PMC2794378.

49. Zhou B, Wang J, Ressom HW. MetaboSearch: tool for mass-based metabolite identification using multiple databases. PLoS One. 2012;7(6):e40096. Epub 2012/07/02. doi: 10.1371/journal.pone.0040096 PONE-D-12-06701 [pii] PMID: 22768229; PubMed Central PMCID: PMC3387018.

50. Huang T, Wei B, Velazquez P, Boronem J, Braun J. Commensal microbiota alter the abundance and TCR responsiveness of splenic naive CD4+ T lymphocytes. Clin Immunol. 2005; 117(3):221–30. Epub 2005/11/18. S1521-6616(05)00337-2 [pii] doi: 10.1016/j.clim.2005.09.012 PMID: 16290233.
